Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colorectal Neoplasms 50Neoplasms 13Neoplasm Metastasis 12Gastrointestinal Stromal Tumors 10Carcinoma, Hepatocellular 7Glioblastoma 5Colonic Neoplasms 5Sarcoma 4Stomach Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Liver Neoplasms 3Rhabdomyosarcoma 2Rectal Neoplasms 2Pancreatic Neoplasms 2Gallbladder Neoplasms 2Esophageal Neoplasms 2Colorectal Cancer Metastatic 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bile Duct Neoplasms 2Advanced Cancer 2Wilms Tumor 1Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Thymoma 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Solid Tumor 1Sarcoma, Ewing 1

Interventions

regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Refractory Solid Tumors × regorafenib × Clear all
NCT04200404 2022-05-06

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

CStone Pharmaceuticals

Phase 1/2 Completed
19 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡